Balancing risk and benefit in heavy drinkers treated with topiramate: Implications for personalized care

Journal of Clinical Psychiatry

Volumn 77, Issue 3, 2016, Pages e278-e282

  Feinn, Richard ^a   Curtis, Brenda ^b   Kranzler, Henry R ^b,c  

^a New York   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Education and Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUK1 KAINATE RECEPTOR; KAINIC ACID RECEPTOR; PLACEBO; TOPIRAMATE; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; FRUCTOSE;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; EUROPEAN AMERICAN; FEMALE; GENE; GRIK1 GENE; HEAVY DRINKING; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CAUCASIAN; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG THERAPY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; NUMBERS NEEDED TO TREAT; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ALCOHOL DRINKING; ANTICONVULSANTS; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FRUCTOSE; GENOTYPE; HUMANS; MALE; NUMBERS NEEDED TO TREAT; POLYMORPHISM, GENETIC; PRECISION MEDICINE; RECEPTORS, KAINIC ACID; RISK ASSESSMENT;

EID: 84963600682     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10053     Document Type: Article

References (25)

1. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. La ncet. 2003;361(9370):1677-1685. doi:10.16/S140-76(03)1370-3 PubMed
2. Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007; 298 (14):1641-1651. doi:10.01/jama.298.641 PubMed
3. Miranda R Jr, MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489-497. doi:10.111/j.1530-07.27.0592.x PubMed
4. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445-452. doi:10.1176/apiajp.20.1308014 PubMed
5. Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014; 38 (6):1481-1488. doi:10.1111/acer.2411 PubMed
6. Del Re AC, Gordon AJ, Lembke A, et al. Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addict Sci Clin Pract. 2013;8(1):12. doi:10.186/194-06408-12 PubMed
7. Anthenelli RM, Blom TJ, McElroy SL, et al. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction. 2008;103(4):687-694. doi:10.11/j.136-04328.02148.x PubMed
8. Oncken C, Arias AJ, Feinn R, et al. Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res. 2014;16(3):288-296. doi:10.93tr/n t41 PubMed
9. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233-240. doi:10.16/j.drugalcdep.2403. 08 PubMed
10. Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013; 70 (12):1338-1346. doi:10.01/jamapsychiatry.2013.295 PubMed
11. Umbricht A, DeFulio A, Winstanley EL, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend. 2014;140: 92-100. doi:10.16/j.drugalcdep.21403.03 PubMed
12. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75(1):34-56. doi:10.16/jbcp.2078.005 PubMed
13. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141-158. doi:10.117/2420986411127 PubMed
14. McNamara JO. Pharmacotherapy of the Epilepsies. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. Chapter 21. New York, NY: McGraw-Hill; 2011.
15. Ray LA, Miranda R Jr, MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17(2):122-129. doi:10.37/a15700 PubMed
16. Sobell L, Sobell M. Timeline followback: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen J P, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. New York, NY: Humana Press; 1992:41-65. doi:10.0/978-14612-037-5-3
17. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22(2):102-110. doi:10.16/S0197-2456(0)0134-3 PubMed
18. Holden WL, Juhaeri J, Dai W. Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiol Drug Saf. 2003;12 (7): 611-616. doi:10.2/pds.887 PubMed
19. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712-720. doi:10.7326/0003-481126-9-197051-00007 PubMed
20. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12): CD001867. PubMed
21. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;(9): CD 004332. PubMed
22. Rehm J, Baliunas D, Borges GL, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010;105(5):817-843. doi:10.1/j.1360-043.21.0289.x PubMed
23. Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAM A. 2004;291(10):1238-1245. doi:10.01/jama.2910.1238 PubMed
24. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev. 2009;(3):CD007954. PubMed
25. Shabaruddin FH, Chen LC, Elliott RA, et al. A systematic review of utility values for chemotherapy-related adverse events. Pharmaco economics. 2013;31(4):277-288. doi:10.107/s4273-01-03-x PubMed